Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) 35.9% HIGHER; Merck (NYSE: MRK) entered into a definitive agreement to acquire Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) for $102 per share in cash, which represents a 35 percent premium to Cubists average stock price for the most recent five trading days.
BioLineRx Ltd. (NASDAQ: BLRX) 18.7% HIGHER; announced today that data from the on-going